Swygert Axis / Signal-Gain Hypothesis: GLP-1 Agonists as Equilibrium Restorers in Cue-Driven Signaling Loops
Swygert Axis / Signal-Gain Hypothesis: GLP-1 Agonists as Equilibrium Restorers in Cue-Driven Signaling Loops
DOI: [To Be Assigned]
February 8, 2026
John Swygert
Abstract
GLP-1 receptor agonists, including semaglutide, are approved for obesity and type 2 diabetes and are known to reduce appetite and body weight. Emerging evidence indicates that their effects extend beyond peripheral satiety signaling into central nervous system circuits involved in reward, motivation, and cue reactivity. This paper proposes a signal-gain hypothesis framed within the Swygert Axis model of equilibrium restoration: GLP-1 agonists function as gain-dampers within cue-driven behavioral signaling loops. Rather than targeting isolated behaviors (e.g., overeating), these agents may attenuate amplification within a shared loop topology—cue → salience → intrusion → action → reinforcement → gain escalation. The hypothesis generates testable predictions across food intake, alcohol use, and potentially gambling behavior. A structured measurement framework is proposed to quantify loop dynamics and enable AI-assisted pharmacologic discovery based on patient-reported signal modulation.
1. Introduction
GLP-1 (glucagon-like peptide-1) receptor agonists have demonstrated significant metabolic efficacy in randomized controlled trials for obesity and diabetes. In addition to peripheral effects on gastric emptying and insulin secretion, GLP-1 receptors are expressed in brain regions including the hypothalamus, nucleus accumbens, ventral tegmental area, and prefrontal cortex—regions implicated in reward processing and salience attribution.
Clinical observations and emerging studies suggest reductions in craving behavior beyond food consumption, including alcohol intake. These findings suggest that GLP-1 signaling may influence motivational salience and reinforcement processes.
2. Loop Topology and the Signal-Gain Hypothesis
2.1 Cue-Driven Behavioral Loop
Compulsive or habitual behaviors can be represented as a feedback loop:
Cue (sensory/contextual/emotional)
→ Salience Assignment
→ Intrusive Replay
→ Somatic Coupling
→ Action Execution
→ Reward Reinforcement
→ Increased Loop Gain
As gain increases, thresholds for activation decrease and cue-triggered behaviors become more automatic.
2.2 Hypothesis
GLP-1 receptor agonists reduce loop gain and/or increase activation thresholds at one or more nodes—particularly at the cue-to-salience and salience-to-intrusion transitions.
The result is reduced compulsion velocity and restoration of behavioral equilibrium.
3. Evidence from Food and Alcohol Domains
3.1 Food
Semaglutide significantly reduces caloric intake and body weight in large randomized trials. Functional imaging and behavioral studies suggest reduced activation in reward-related brain regions in response to food cues.
3.2 Alcohol
Recent randomized controlled data indicate that semaglutide reduces alcohol craving and consumption in individuals with alcohol use disorder. This supports the possibility that GLP-1 signaling modulates cue reactivity beyond metabolic contexts.
4. Proposed Extension to Gambling
Gambling behavior is strongly cue-driven (visual stimuli, notifications, environmental triggers, near-miss events). If GLP-1 agonists attenuate cue salience amplification, predicted outcomes include:
Reduced spontaneous gambling ideation
Increased delay between cue exposure and wagering
Reduced escalation after losses
Decreased compulsion velocity
While neurochemical pathways differ between domains, loop topology remains conserved.
5. Testable Predictions
Reduced daily intrusive craving frequency
Lower cue reactivity ratings
Increased cue-to-action latency
Reduced reinforcement amplification
Reduced behavioral escalation patterns
Potential adverse effects to monitor:
Anhedonia
Blunted affect
Mood changes
Sleep disturbance
6. Measurement Framework
Daily structured metrics:
Intrusion Count (per domain per day)
Cue Reactivity Rating (0–10 scale)
Action Delay (minutes or no-action outcome)
Somatic Coupling Rating (0–10)
Reinforcement Afterglow Rating (0–10)
These measures can be aggregated longitudinally to estimate loop gain changes.
7. AI-Assisted Phenomenology Capture
A structured AI system can:
Extract cue types from patient narrative
Quantify intrusion frequency
Detect emergent therapeutic effects
Identify unexpected cross-domain modulation
Track adverse signal dampening
This approach operationalizes patient-reported signal modulation into analyzable datasets.
8. Limitations
Not all compulsive behaviors share identical biological pathways.
Dose-response relationships may vary.
Long-term effects on reward sensitivity require further study.
Gambling effects remain hypothetical pending direct trials.
Conclusion
GLP-1 receptor agonists may represent pharmacologic gain-dampers within cue-driven behavioral signaling loops. Framing their effects in control-systems terms provides a unifying topology across domains such as food, alcohol, and potentially gambling. The signal-gain hypothesis generates testable predictions and supports the integration of AI-assisted patient-experience quantification to identify emergent therapeutic applications.
References
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216.
Klausen MK, et al. Effect of Semaglutide on Alcohol Consumption in Individuals with Alcohol Use Disorder: Randomized Clinical Trial. JAMA Psychiatry. 2024.
Dickson SL, et al. The Glucagon-Like Peptide 1 (GLP-1) System and Reward. Neuroscience & Biobehavioral Reviews. 2012;36:1221–1237.
Hernandez NS, et al. GLP-1 Receptor Activation in Mesolimbic Pathways Reduces Food and Drug Reward. Physiology & Behavior. 2018;192:1–9.
Comments
Post a Comment